NOTE 7 – SUBSEQUENT EVENTS

In March 2017, the Company entered into an engagement agreement with a law firm to provide it with legal services related to the Company’s potential intellectual property. In connection with this agreement on April 13, 2017, the Company entered into a Securities Purchase Agreement pursuant to which the Company sold 400,000 common shares for an aggregate price of $400, $0.001 per share to a member of the firm, which has been paid in full. The agreement contains a clawback provision requiring the individual to sell back a portion of the shares through the fourth anniversary of the law firm’s appointment.

Effective March 22, 2017, the Company entered into an agreement with a consultant to provide services to the Company in connection with the development of technology and intellectual property for developing a leading position for plant and synthetic derived cannabinoid therapeutics for human clinic trials.

On April 3, 2017, the Company appointed a new President, Chief Executive Officer and Director. In connection with the appointment, the Company entered into a Securities Purchase Agreement pursuant to which the Company sold 1,760,000 common shares for an aggregate price of $1,760, $0.001 per share to the individual, which has been paid in full. The agreement contains a clawback provision requiring the individual to sell back a portion of the shares through the fourth anniversary of his appointment.